Dimerix names Dr David Fuller as chief medical officer

Melbourne, Australia-based Dimerix (ASX: DXB) has appointed Dr David Fuller as chief medical officer (CMO), effective immediately.

Dr Fuller is an internationally experienced pharmaceutical executive and physician with over 30 years’ experience across pre-clinical and clinical development, as well as medical and regulatory affairs, and was the former CMO of Race Oncology. Dr Fuller, who has a strong fundamental background in the Dimerix technology having worked with Dimerix prior to public listing, will be responsible for the strategic delivery of the company’s flagship ACTION3 Phase III clinical program for focal segmental glomerulosclerosis (FSGS) kidney disease currently recruiting globally. His extensive experience and background across clinical trial, pharmacovigilance and regulatory strategy as a biopharmaceutical executive and physician will be instrumental as Dimerix continues to commercialise the asset.

“With our first licensing transaction now secured, and the first analysis outcome anticipated in March 2023, Dimerix has entered a new commercialization era. We are absolutely delighted to welcome David to our team, who has a strong and proven track record in large, global clinical trials and has led several successful market approvals,” said Dr Nina Webster, chief executive and managing director of Dimerix.